A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 23, Issue 2, Pages 508-516
Publisher
Oxford University Press (OUP)
Online
2011-04-29
DOI
10.1093/annonc/mdr151
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- NVP-BEZ235 as a New Therapeutic Option for Sarcomas
- (2010) M. C. Manara et al. CLINICAL CANCER RESEARCH
- Osteosarcoma
- (2010) Richard Gorlick et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high-risk osteosarcoma patients
- (2009) Berger Massimo et al. CANCER
- Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma
- (2009) Ayesha Abdeen et al. CANCER
- Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma
- (2009) Alexander J. Chou et al. CANCER
- [F-18]-fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults
- (2009) Douglas S. Hawkins et al. CANCER
- Novel therapeutic agents for osteosarcoma
- (2009) Kathleen O’Day et al. Expert Review of Anticancer Therapy
- Absence of Progression As Assessed by Response Evaluation Criteria in Solid Tumors Predicts Survival in Advanced GI Stromal Tumors Treated With Imatinib Mesylate: The Intergroup EORTC-ISG-AGITG Phase III Trial
- (2009) Axel Le Cesne et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas
- (2009) Robert G. Maki et al. JOURNAL OF CLINICAL ONCOLOGY
- Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)
- (2009) Stefan Sleijfer et al. JOURNAL OF CLINICAL ONCOLOGY
- From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
- (2009) R. L. Wahl et al. JOURNAL OF NUCLEAR MEDICINE
- Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways
- (2009) Ymera Pignochino et al. Molecular Cancer
- Gastrointestinal Stromal Tumors II: Medical Oncology and Tumor Response Assessment
- (2009) Robert S. Benjamin et al. SEMINARS IN ONCOLOGY
- The Loss of Radiographic Enhancement in Primary Renal Cell Carcinoma Tumors Following Multitargeted Receptor Tyrosine Kinase Therapy is an Additional Indicator of Response
- (2009) C. Lance Cowey et al. UROLOGY
- Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma
- (2008) Tadahiko Kubo et al. CANCER
- Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma
- (2008) Fariba Navid et al. CANCER
- Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group
- (2008) Paul A. Meyers et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started